

Neuralstem, Inc.
Form 8-K
May 23, 2014

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): May 23, 2014 (May 23, 2014)

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

| | | |
|---|------------------------------|--|
| Delaware | 000-1357459 | 52-2007292 |
| (State or other jurisdiction of incorporation or organization) | (Commission File No.) | (IRS Employee Identification No.) |

20271 Goldenrod Lane, 2nd Floor,

Germantown, Maryland 20876

(Address of Principal Executive Offices)

(301) 366-4960

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.

Other Events.

On May 23, 2014, Neuralstem, Inc. (“Company”) announced that data from the NSI-189 Phase Ib study in major depressive disorder will be presented at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Florida on June 17th, 2014. A copy of the press release is attached to this report as Exhibit 99.01.

Item 9.01

Financial Statement and Exhibits.

| Exhibit Number | Description |
|---------------------------|--------------------|
|---------------------------|--------------------|

| | |
|-------|----------------------------------|
| 99.01 | Press Release Dated May 23, 2014 |
|-------|----------------------------------|

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr
I. Richard Garr
Chief Executive Officer

Dated: May 23, 2014

INDEX OF EXHIBITS

| Exhibit Number | Description |
|---------------------------|----------------------------------|
| 99.01 | Press Release Dated May 23, 2014 |